Last revised by Daniel J Bell on 12 Dec 2022

Gadopiclenol (also known by its brand names Elucirem or Vueway) is a new (late 2022) extracellular intravenous gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging.

  • macrocyclic, non-ionic molecule

  • 100% renally excreted

  • T1 relaxivity: 12.8 mM·s at 1.5 T and 11.6 mM·s at 3 T

  • concentration: 0.5 mmol/mL

  • recommended dosage: 0.05 mmol/kg


As a new extracellular contrast agent, the MRI studies for which gadopiclenol may be useful are still being explored. It has potential for a wide range of studies of both the CNS and body.

Gadopiclenol has a much higher T1 relaxivity than other GBCAs currently used, and therefore can be used at a lower dosage and this is felt to be one of its main strengths. It may reduce the potential risk attributed to deposition of free gadolinium in soft tissues as there will be less gadolinium to be deposited.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.